東陽光藥(01558.HK)吐逾7%曾失43元 成交倍增
斥逾20億人民幣收購系內公司兩種治療2型糖尿病產品的東陽光藥(01558.HK)反彈受制10天線後,今天股價失守20天線(26.22元),沽盤持續湧現,最多挫9.1%低見42.6元喘定,現造43.5元,急吐7.2%,成交倍增至337萬股,涉資1.48億元。
東陽光藥上周中公布關連交易,以現金總代價代價20.57億人民幣向系內的廣東東陽光藥業收購兩種治療2型糖尿病產品,包括焦谷氨酸榮格列淨及利拉魯(月太),彼即將開展三期臨床試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.